Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | N-3C01 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on N-3C01 (Jun 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| N-3C01 | N3C01|N3 C01|N 3C01 | Limited information is currently available on N-3C01 (Jun 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07639450 | Phase Ib/II | N-3C01 + Pembrolizumab N-3C01 | N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors (Solid Tumors) | Not yet recruiting | AUS | 1 |